A citation-based method for searching scientific literature

Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli, Jessica Read, Peter Langmuir, Anderson J Ryan, Martin J Schlumberger. J Clin Oncol 2012
Times Cited: 839



Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson, Kevin J Wilson, Lucian DiPietro, Paul Fleming, Michael Palmer, Mimi I Hu, Lori Wirth, Marcia S Brose, Sai-Hong Ignatius Ou, Matthew Taylor, Elena Garralda, Stephen Miller, Beni Wolf, Christoph Lengauer, Timothy Guzi, Erica K Evans. Cancer Discov 2018
Times Cited: 187




List of shared articles



Times cited

Multiple endocrine neoplasia type 2: A review.
Jes Sloth Mathiesen, Grigoris Effraimidis, Maria Rossing, Åse Krogh Rasmussen, Lise Hoejberg, Lars Bastholt, Christian Godballe, Peter Oturai, Ulla Feldt-Rasmussen. Semin Cancer Biol 2022
5

Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.
Pietro Locantore, Roberto Novizio, Andrea Corsello, Rosa Maria Paragliola, Alfredo Pontecorvi, Salvatore Maria Corsello. Expert Opin Drug Discov 2022
2

Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells.
Seung-Keun Hong, Dmytro Starenki, Oleta T Johnson, Jason E Gestwicki, Jong-In Park. Int J Mol Sci 2022
1

Nutrition in Advanced Thyroid Cancer Patients.
Laura Agate, Elisa Minaldi, Alessio Basolo, Valentina Angeli, Roberta Jaccheri, Ferruccio Santini, Rossella Elisei. Nutrients 2022
0

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei. Front Endocrinol (Lausanne) 2022
1

Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
Mian Liu, Pei Chen, Hui-Yu Hu, Deng-Jie Ou-Yang, Rooh-Afza Khushbu, Hai-Long Tan, Peng Huang, Shi Chang. J Cancer Res Clin Oncol 2021
3

Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach.
Adam S Fisch, Israa Laklouk, Masato Nakaguro, Vânia Nosé, Lori J Wirth, Daniel G Deschler, William C Faquin, Dora Dias-Santagata, Peter M Sadow. Hum Pathol 2021
2

Discovery and optimization of selective RET inhibitors via scaffold hopping.
Zhibo Luo, Lingli Wang, Zhifei Fu, Bin Shuai, Miaorong Luo, Guoping Hu, Jian Chen, Jikui Sun, Jiansong Wang, Jian Li,[...]. Bioorg Med Chem Lett 2021
0

ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.
Michelle D Williams, Junsheng Ma, Elizabeth G Grubbs, Robert F Gagel, Rozita Bagheri-Yarmand. Am J Cancer Res 2021
0

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Marialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, Brendan Frett, Nicholas McConnell, Lingtian Zhang, Annalisa Brescia, Giorgia Federico, Lingzhi Zhang, Paolo Salerno,[...]. Sci Rep 2021
0

Precision therapy for RET-altered cancers with RET inhibitors.
Kyaw Z Thein, Vamsidhar Velcheti, Blaine H M Mooers, Jie Wu, Vivek Subbiah. Trends Cancer 2021
8

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Debasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, Baku Acharya, Noemi Garcia Garcia, Erica Lane Smith, Brendan Frett. J Med Chem 2021
1

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
Yaogeng Wang, Rolf W Sparidans, Sander Potters, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. Pharmacol Res 2021
2